NAALADase Inhibitors
Learn MoreHIF-PH inhibitors are powerful tools in the field of biotechnology that have the ability to modulate hypoxia signaling pathways Hypoxia-inducible factor (HIF) is a transcription factor that plays a key role in cellular responses to low oxygen levels HIF-PH inhibitors work by inhibiting the activity of prolyl hydroxylase an enzyme that regulates the degradation of HIF By blocking the degradation of HIF these inhibitors stabilize the protein leading to the activation of downstream genes involved in angiogenesis and metabolism These inhibitors have gained significant attention in the development of therapeutic strategies for a range of conditions including anemia kidney disease and cancer
Catalog Number | Chemical Name | CAS # | Price |
---|---|---|---|
EI-0747 | DMOG | 89464-63-1 | Online Inquiry |
EI-0977 | FG-4592 | 808118-40-3 | Online Inquiry |
EI-1220 | IOX2 | 931398-72-0 | Online Inquiry |
EI-1221 | IOX3 (FG-2216) | 223387-75-5 | Online Inquiry |
EI-1258 | JNJ-42041935 | 1193383-09-3 | Online Inquiry |
HIF-PH Inhibitors have a wide range of applications in both research and medicine In research these inhibitors are utilized to study the hypoxia-inducible factor (HIF) pathway and its role in various biological processes By inhibiting the activity of HIF-PH scientists can better understand how this pathway affects gene expression cell metabolism and adaptation to low oxygen conditions
In medicine HIF-PH inhibitors hold promise as a potential treatment for conditions related to insufficient oxygen supply such as anemia and ischemic diseases By blocking HIF-PH these inhibitors stabilize HIF leading to increased production of erythropoietin a hormone that stimulates the production of red blood cells This can be beneficial for patients with chronic kidney disease or those undergoing chemotherapy-induced anemia
Additionally HIF-PH inhibitors are being investigated as a therapy for cancer By inhibiting HIF-PH these inhibitors can disrupt tumor angiogenesis and promote the immune response against cancer cells This approach shows potential for enhancing the efficacy of existing cancer treatments and overcoming resistance to therapy
Overall HIF-PH inhibitors offer exciting possibilities for both research and therapeutic applications with the potential to improve our understanding of biological processes and provide new avenues for treating various diseases
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.